Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia

P A Courtney, A D Crockard, K Williamson, A E Irvine, R J Kennedy, A L Bell

Abstract

Objective—To quantify the percentage of apoptotic peripheral blood neutrophils in systemic lupus erythematosus (SLE) and to determine the relations with disease activity and neutropenia.

Methods—Neutrophil apoptosis in SLE patients (n =50) was assessed by flow cytometry using annexin V binding and fluorescent labelled anti-fas. Rheumatoid arthritis (RA, n =20) and inflammatory bowel disease patients (IBD, n =20) were studied as disease controls.

Results—The percentage of apoptotic neutrophils, determined by annexin V binding, was increased in peripheral blood of SLE patients (median = 3.25%) compared with normal healthy donors (n =20, median = 1.20%) and disease controls (RA: median = 1.15%) (IBD: median = 1.15%). SLE neutrophil apoptosis correlated positively with lupus disease activity measured by SLAM score. SLE patients with increased antibodies to dsDNA (>10 mg/ml) had increased apoptotic neutrophils. Eight of 14 neutropenic SLE patients had increased apoptotic neutrophils. Increased neutrophil fas expression compared with normal controls was observed in SLE, RA, and IBD.

Conclusion—Neutrophil fas expression is increased non-specifically in inflammatory disease. Increased circulating apoptotic neutrophils in SLE correlate positively with disease activity (SLAM) and may contribute to autoantigen excess including dsDNA.

(Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by diverse clinical features and the presence of autoantibodies in the serum. The pathogenesis remains unknown but exposure to an environmental trigger, in association with a defined genetic background, may lead to profound changes in the immune system. There is increasing evidence that these changes include defective phagocytosis mechanisms and increased apoptotic leucocytes.

Apoptosis is a carefully governed process that brings about cell death in a regulated physiological context without the release of inflammatory mediators. The morphological changes of apoptosis are defined and include contraction of chromatin with nuclear and cytoplasmic budding occurring to form membrane bound fragments or apoptotic bodies. The autoantigens of human SLE, (Ro, La, dsDNA, RNP, etc) are exposed on the surface of apoptotic keratinocytes as a result of this sequence of events. Therefore, increased apoptotic cells could contribute to autoantigen excess in SLE.

Early during the process of apoptosis leucocytes lose their phospholipid membrane asymmetry that leads to externalisation of phosphatidylserine. This membrane change is one of the mechanisms by which phagocytic cells identify apoptotic cells. Experimental evidence indicates that membrane asymmetry detected by annexin V is a very early and specific phenomenon during apoptosis, occurring before the typical morphological changes are apparent. Phosphatidylserine can be detected using annexin V, which is a calcium dependent phospholipid binding protein with high affinity for phosphatidylserine. When annexin V is conjugated to a fluorochrome such as fluorescein isothiocyanate the number of apoptotic cells can be enumerated by flow cytometry. Increased apoptotic lymphocytes have been reported in SLE by this method and it has been suggested that this may be caused by defective clearance by macrophages.

Neutrophil apoptosis is mediated by fas (APO-1/CD95) and fas ligation is associated with widespread phosphatidylserine expression on the cell surface. The fas gene was first described in MRL mice with a lymphoproliferative syndrome including features resembling human SLE. The human fas gene counterpart (APO-1/CD95) is located on the long arm of chromosome 10 and encodes a transmembrane receptor that, after fas ligand binding actively mediates apoptosis via its cytoplasmic domain. This discovery stimulated the study of apoptosis regulation, but structural abnormalities of apoptotic genes have not been identified to date in human SLE, although they do occur in rare familial disorders. In human SLE increased lymphocyte fas expression has been reported but it may not be disease specific. Fas expression has not previously been studied on SLE neutrophils.

Lupus associated neutropenia (neutrophil count below 1.8 per n/l, in the absence of cytotoxic drugs) has been reported in at least 20% of SLE patients and neutrophil apoptosis has not previously been studied as a potential contributing factor. Given the role of colony stimulating factors in promoting survival of
neutrophils by suppressing apoptosis, in addition to granulopoietic properties, the interactions of these factors have also been studied.

We present data on fas expression and numbers of apoptotic neutrophils in SLE. Disease activity and drug treatment have been recorded and correlated with data about apoptosis. In addition to studying normal control samples, we have measured a rheumatic chronic inflammatory disease control group (rheumatoid arthritis) and a non-rheumatic chronic inflammatory disease control group (inflammatory bowel disease) in an attempt to discover the specificity of changes seen.

Methods
PATIENTS AND CONTROLS
All SLE patients (n=50) fulfilled ARA criteria for diagnosis and were recruited from outpatient clinics and rheumatology inpatient wards. Disease controls, rheumatoid arthritis (RA) (n=20) and inflammatory bowel disease (IBD) (n=20) patients were recruited from rheumatology and surgical outpatients respectively and inpatient wards. Patients with disease flare ups were studied before the institution of additional drug treatment. SLE patients taking cytotoxic drugs were excluded from the study. Written informed consent was obtained from all patients. Age and sex matched normal healthy volunteers were recruited from hospital staff.

CLINICAL INFORMATION
Clinical features were recorded after full clinical examination and lupus patients were assigned precise diagnostic subgroups where appropriate. SLE disease activity was assessed by SLAM (Systemic Lupus Activity Measure) and BILAG (British Isles Lupus Activity Guide). These indices have been validated and possess psychometric properties appropriate for clinical research. The SLAM index covers symptoms that occurred during the previous month and includes 24 clinical and eight laboratory parameters to evaluate organs that cannot otherwise be assessed. The BILAG scale consists of eight symptom based groups and additional laboratory parameters. Previous organ involvement is included in the BILAG score. Drug treatment and prednisolone dose were recorded for all patients. Serum antibodies to dsDNA were measured by a commercial assay using the Farr technique (ImmunoDiagnostics). Rheumatoid arthritis disease activity was assessed by erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and Ritchie articular index. IB activity was assessed by ESR and CRP.

CELL PREPARATION
Peripheral blood was sampled and layered on equal volumes of Histopaque 1119 and Histopaque 1077 (Sigma) to obtain an enriched granulocyte layer. Cells were washed in PBS and counted before labelling.

NEUTROPHIL MORPHOLOGY
Cytocentrifuge slides were prepared (n=10) within four hours of venepuncture to confirm the presence of neutrophils with morphological features of apoptosis. Slides were stained with modified Wright stain and apoptotic neutrophils counted under high power view in 500 cells.

IMMUNOFLUORESCENCE LABELLING
Fas, CD15: Aliquots of 100 µl cell suspension (5x10^6 cells/ml) were incubated for 60 minutes at 4°C with 10 µl anti-fas-FITC (Immunotech), 10 µl MsIgG1-FITC (Immunotech) or 20 µl anti-CD15-PE (Coulter) respectively. MsIgG1 was used as an isotype control for anti-fas to allow subtraction of non-specific staining. After two washes in phosphate buffered saline (PBS) the cells were resuspended in PBS before flow cytometric analysis.

Annexin V: Aliquots of 100 µl cells (5x10^6 cells/ml) were suspended in binding buffer (R and D) and incubated for 20 minutes with annexin V-FITC (R and D) and propidium iodide (R and D). Immediate flow cytometric analysis was performed.

FLOW CYTOMETRY
Flow cytometric analyses were performed on a Coulter EPICS ELITE flow cytometer that was standardised for inter-and intra-run variability by calibration with Immunotech fluorospheres (Coulter). Neutrophils were identified on the basis of light scatter properties and CD15 positivity (>95%). Five thousand neutrophils were analysed per sample and the percentage of fas positive cells determined after subtraction of non-specific staining as identified by the isotype control histogram.

Dual colour histograms were analysed for annexin V/propidium iodide labelled cells and the percentages of apoptotic (FITC’PI’) and necrotic (FITC’PI’) cells determined (fig 1).
DETERMINATION OF SERUM GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) AND GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF)

Serum G-CSF and GM-CSF were measured by ELISA (Quantikine Immunoassay) according to the manufacturer’s instructions.

STATISTICAL ANALYSIS

The statistical significance of the results was determined using the Mann-Whitney test for unpaired samples. Spearman correlation coefficients were used to study the relations between disease activity or treatment and apoptosis measures.

Results

ANNEXIN V

There was a significant increase of apoptotic neutrophils (fig 2) as assessed by the annexin V assay in SLE patients (n=50, median =3.25, interquartile range 2.28–5.23) compared with normal controls (n=20, median = 1.20, interquartile range 0.43–1.88; p = 0.001), RA patients (n=20, median =1.15, interquartile range 0.38–4.40; p = 0.008), and IBD patients (n=20, median =1.15, interquartile range 0.10–2.95; p = 0.008). There was no significant difference in the number of apoptotic neutrophils between the RA (p=0.75) or IBD (p=0.68) and normal control groups.

NEUTROPHIL MORPHOLOGY

The correlation observed between the percentage of apoptotic neutrophils by morphology (n=10) and by annexin V in individual patients was not statistically significant (r=−0.59, p=0.07; Spearman). The morphology data were also assessed in two groups: (<2% apoptotic neutrophils, mean 1.4%, n=5) and (>2% apoptotic neutrophils, mean 2.8%, n=5). The first group (<2%) had a mean percentage annexin positivity of 2.6% and the second group (>2%) had a mean percentage annexin positivity of 5.2% suggesting that patients with increased numbers of apoptotic cells by annexin V also had increased apoptotic cells by morphology. The percentage of apoptotic neutrophils was higher, in all samples (n=10) by annexin V (mean = 3.6%) than by morphology (mean =1.7%).

FAS

Neutrophil fas expression (fig 3) was significantly increased in SLE (median =30.1, IQ range 18.00–53.58; p =0.002), RA (median =32.85, IQ range 22.18–39.98; p=0.001), and IBD (median =28.95, IQ range 23.00–41.48; p =0.006) compared with normal controls (median=17.8, IQ range 8.50–24.93). There was no significant difference between neutrophil fas expression in either RA or IBD when compared with SLE (p=0.88 and p=0.68 respectively). There was a positive correlation between SLE neutrophil fas expression and neutrophil annexin positivity (r=0.52, p=0.01).

DISEASE ACTIVITY

SLE

At the time of study 10 patients had inactive disease (SLAM <6), 26 had moderately active disease (SLAM 6–12), and 14 had active disease (SLAM >12) .

Correlations of SLE apoptotic neutrophil count and fas expression with disease activity measures were determined. There was a positive correlation between annexin V positive neutrophils and SLAM (r =0.50, p = 0.001) (fig 4). When the outlier point in figure 4 was eliminated the Spearman’s correlation coeffi-
and SLE disease activity measures (SLAM: \( r= 0.25, p=0.08 \)).

**RELATION OF NEUTROPENIA TO G-CSF AND GM-CSF**

Circulating G-CSF was increased in four of eight patients with neutropenia. Details of the neutropenic patients are recorded in Table 1. G-CSF concentrations were increased in two lupus patients without neutropenia but were within the normal range in other lupus patients (n = 6), RA patients (n = 4) and normal controls (n = 6) (data not shown). GM-CSF concentrations were within the normal range (<7.8 pg/ml) in all samples.

**TREATMENT**

To analyse the possible effects of treatment on the apoptotic cell counts we correlated the number of apoptotic cells with the corticosteroid dose (range 0–60 mg). Twenty SLE, 13 RA, and 12 IBD patients were taking corticosteroids at the time of sampling.

There was no significant inverse correlation between corticosteroid dose and neutrophil apoptosis (\( r = -0.32, p = 0.14 \)). When patients were classified as those taking high dose corticosteroids (>7.5 mg), those taking low dose corticosteroids (<7.5 mg) and those taking no corticosteroid there was a significant difference in apoptotic neutrophil count between the no corticosteroid group (median 5.3%) and the high dose corticosteroid group (median = 2.3%, \( p = 0.02 \)). Four patients with active disease including neutropenia were studied before treatment and again six weeks after being established receiving corticosteroid treatment. Reduced disease activity coincided with decreased neutrophil fas expression and decreased apoptotic neutrophil count. However, a large study would be necessary to assess the effects of corticosteroids on neutrophil apoptosis in SLE.

**Discussion**

This study shows a significantly higher level of circulating apoptotic neutrophils in SLE compared with normal controls and disease controls (RA and IBD). The experimental design with FITC-annexin V staining of freshly isolated neutrophils was used to detect apoptotic cells at an earlier stage than morphology. Taken with the reported finding of high concentrations of circulating early apoptotic peripheral blood mononuclear cells, this study is concordant with the suggestion that impaired clearance of apoptotic material may be a specific hallmark of SLE. In addition, or alternatively, increased neutrophil apoptosis may be occurring.

For example positive correlations were observed between apoptotic neutrophil counts

---

**Table 1** Annexin, fas, SLAM, and colony stimulating factor data for neutropenic SLE patients (n =14)

<table>
<thead>
<tr>
<th>Neutrophil count</th>
<th>fas</th>
<th>annexin</th>
<th>SLAM</th>
<th>G-CSF (pg/ml)</th>
<th>GM-CSF (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.08×10⁶/μl</td>
<td>99.0</td>
<td>6.3</td>
<td>18</td>
<td>291.90</td>
<td>2.85</td>
</tr>
<tr>
<td>1.80</td>
<td>41.2</td>
<td>7.8</td>
<td>19</td>
<td>69.93</td>
<td>0.09</td>
</tr>
<tr>
<td>1.40</td>
<td>69.1</td>
<td>11.1</td>
<td>27</td>
<td>53.4</td>
<td>1.47</td>
</tr>
<tr>
<td>1.80</td>
<td>24.0</td>
<td>2.2</td>
<td>6</td>
<td>53.50</td>
<td>1.47</td>
</tr>
<tr>
<td>1.30</td>
<td>21.8</td>
<td>3.0</td>
<td>8</td>
<td>28.14</td>
<td>0.18</td>
</tr>
<tr>
<td>1.30</td>
<td>5.4</td>
<td>2.2</td>
<td>8</td>
<td>1.00</td>
<td>0.00</td>
</tr>
<tr>
<td>1.40</td>
<td>27.1</td>
<td>3.1</td>
<td>7</td>
<td>28.74</td>
<td>0.25</td>
</tr>
<tr>
<td>1.80</td>
<td>22.2</td>
<td>—</td>
<td>15</td>
<td>20.21</td>
<td>0.92</td>
</tr>
<tr>
<td>1.02</td>
<td>99.0</td>
<td>22.0</td>
<td>34</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>1.36</td>
<td>53.3</td>
<td>1.9</td>
<td>17</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>1.70</td>
<td>43.2</td>
<td>2.8</td>
<td>8</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>0.72</td>
<td>54.4</td>
<td>11.1</td>
<td>22</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>1.80</td>
<td>49.0</td>
<td>5.3</td>
<td>5</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>1.70</td>
<td>37.2</td>
<td>4.2</td>
<td>13</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>
Increased apoptotic peripheral blood neutrophils in SLE

and SLE disease activity measures. Although increased apoptotic lymphocytes have been reported in SLE, it is not clear if there is a correlation with disease activity and one study has reported the presence of apoptotic monocytes in the circulation of patients with active lupus. The finding of increased numbers of apoptotic neutrophils in the peripheral circulation could be more important as neutrophils are numerically greater and have a reduced life span compared with mononuclear cells. Therefore, increased apoptotic neutrophils could be a greater potential source of lupus specific autoantigens and failure of clearance could trigger or exacerbate SLE. Our demonstration of increased apoptotic neutrophils provides one possible mechanism for the increase in antibodies to ds DNA in SLE. However, increased antibodies to dsDNA are associated with disease flares and the increased apoptotic neutrophils may not directly result in antibody formation. This study, however, showed a statistically stronger correlation between dsDNA antibodies and apoptotic neutrophils than between dsDNA and disease activity.

Fas expression was also increased in RA and IBD, which suggests that switching on of neutrophil death genes may be a general characteristic of inflammatory disorders designed to contribute to pathways of inflammatory resolution. Indeed, our group have previously shown that inflammatory synovial fluid contains a factor or factors capable of promoting neutrophil apoptosis. However, the inhibitory effect of corticosteroids on neutrophil apoptosis does not fit easily with proposed anti-inflammatory mechanisms of action. In contrast with the effect on neutrophil apoptosis, corticosteroids are inducers of apoptosis in lymphoid cells.

There was a discrepancy between neutrophil fas expression in normal controls between this study and that reported by Iwai et al, who reported that neutrophils expressed fas constitutively. Fas expression on mononuclear cells was comparable (data not shown) and the differences for neutrophils may reflect the immediate staining and analyses performed in this study as neutrophils rapidly express fas and undergo apoptosis after removal from the circulation.

The discrepancy between annexin V positive neutrophils in SLE and RA requires explanation. The relation between neutrophil fas expression and apoptosis is likely to be influenced by multiple factors and not all fas engagement necessarily results in apoptosis. The regulation of apoptosis is complex and pathways other than fas can activate machinery for cell death. In addition, serum soluble fas can protect cells from fas mediated apoptosis, so additional regulatory input occurs within the fas pathway itself.

Apoptotic cell clearance is now the focus of attention in SLE. There is evidence of a decreased phagocytic clearance of apoptotic cells but this will require further evaluation. Savill et al have reported in vitro uptake of apoptotic neutrophils by macrophages in normal controls and some cases of inflammatory arthritis to be similar but this method has not yet been applied in SLE. The macrophage receptor involved with the uptake of apoptotic cells is being defined and this may facilitate investigation of a specific defect in lupus. The clearance of apoptotic cells does not usually cause activation of the immune system and phagocytic cells have enormous capacity to engulf apoptotic material effectively and rapidly. However, in the situation of impaired phagocytosis or increased apoptosis an overwhelming quantity of antigenic material from apoptotic bodies may lead to a permanent challenge to natural tolerance. The presence of large quantities of nucleosomes may result in the presentation of lupus specific autoantigens to autoreactive T cells. In genetically susceptible people this sequence of events may result in polyclonal B lymphocyte stimulation and autoantibody responses typical of SLE, leading to the induction and maintenance of autoimmunity.

SLE associated neutropenia is likely to be multifactorial. Normal or hyperplastic granulopoiesis has been reported in untreated SLE neutropenia; most recently in all of nine patients successfully treated with recombinant G-CSF. Patients with SLE can also exhibit diminished granulopoiesis and a hypocellular marrow attributable to myelofibrosis or aplasia. Circulating anti-neutrophil antibodies occur in SLE but their presence in patients with and without neutropenia suggests they are not the most important factor responsible.

Neutrophil apoptosis has not previously been studied as a potential contributing factor to SLE neutropenia. The suppression of neutrophil apoptosis by effective treatments of SLE neutropenia such as recombinant granulocyte colony stimulating factor and corticosteroids are in keeping with this theory.

Serum G-CSF is increased in other neutropenic disease states and this study suggests that G-CSF is increased in some patients with lupus neutropenia but not in others. The possibility exists that increased neutrophil apoptosis may aggravate some cases of lupus neutropenia associated with active disease. However, the increased apoptotic neutrophils demonstrated in these patients may be a result of disease activity and neutropenia may occur by different mechanisms. No significant conclusion could be reached regarding the relation between neutrophil apoptosis, SLE neutropenia, and G-CSF concentrations from this study.

Corticosteroid treatment was associated with reduced apoptotic neutrophils, which would have been predicted given the findings of in vitro studies. The inhibition of neutrophil apoptosis may represent an important mechanism of action in the treatment of disease flares in SLE.

The finding of increased circulating peripheral blood apoptotic neutrophils that correlates with SLE disease activity keeps the process of apoptosis at the centre of pathogenetic interest in the generation of autoantibodies. The apop-
tosis related sequelae of experimental treatments are already the focus of attention and the development of new therapeutic modalities in rheumatic diseases may be orientated towards the biological regulation of cell survival.

Funding: this work was supported by LUPUS UK and a Royal Victoria Hospital, Belfast, Research Fellowship.

The authors thank Dr S A McMillan for his assistance in the measurement of antibodies to dsDNA.


3 Peroni A, Wiedenkamp F, Herrmann M, Specker C, Schneider M. High levels of circulating early apoptotic peripheral blood mononuclear cells in SLE. Lupus 1998;7:113–18.


